Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026)

Alnylam Pharmaceuticals' Raw Materials history runs 9 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• Quarterly Raw Materials fell 50.05% year-over-year to $11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (down 50.05% YoY) and the FY2025 annual result came in at $14.2 million, down 40.81% from the prior year.
• Raw Materials was $11.7 million for Q1 2026 at Alnylam Pharmaceuticals, down from $14.2 million in the prior quarter.
• Across five years, Raw Materials topped out at $26.0 million in Q2 2024 and bottomed at $11.7 million in Q1 2026.
• A 5-year average of $20.9 million and a median of $22.3 million in 2022 frame the typical range for Raw Materials.
• Peak annual rise in Raw Materials reached 51.25% in 2022, while the deepest fall reached 72.81% in 2022.
• Alnylam Pharmaceuticals' Raw Materials stood at $22.3 million in 2022, then advanced by 4.62% to $23.3 million in 2023, then gained by 2.65% to $24.0 million in 2024, then tumbled by 40.81% to $14.2 million in 2025, then declined by 17.6% to $11.7 million in 2026.
• Business Quant data shows ALNY's Raw Materials at $11.7 million in Q1 2026, $14.2 million in Q4 2025, and $22.3 million in Q3 2025.